Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands

Biologics in Therapy
doi 10.1007/s13554-012-0007-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cost-Minimization Analysis of Infliximab Versus Adalimumab in the Treatment of Crohn’s Disease and Ulcerative Colitis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Cost-Utility Analysis of Infliximab and Adalimumab for Refractory Ulcerative Colitis

Cost Effectiveness and Resource Allocation
Health Policy
2009English

Cost-Effectiveness of Early Assisted Discharge for COPD Exacerbations in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Has Infliximab Influenced the Course and Prognosis of Acute Severe Ulcerative Colitis?

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2019English

Letter: Dose Optimising Infliximab in Acute Severe Ulcerative Colitis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Psy100 - Cost-Effectiveness Analysis of Second Line Treatment for Patients With Ulcerative Colitis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Letter: Should We Intensify Infliximab in Acute Severe Ulcerative Colitis?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Golimumab for the Treatment of Ulcerative Colitis

Expert Opinion on Biological Therapy
Drug DiscoveryClinical BiochemistryPharmacology
2017English

A Type II Segmental Vitiligo Developed Under Infliximab Treatment for Ulcerative Colitis

Annals of Dermatology
Dermatology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy